U.S. Department of Health and Human Services

Molecular and Clinical Hematology Branch

Griffin Rodgers, Chief

​​​​​​​​​​​​​

Laboratories

Molecular Hematology Section

Griffin Rodgers

Dr. Griffin P. Rodgers, director of the NIDDK, is also chief of the Molecular and Clinical Hematology Branch (MCHB) and Molecular Hematology Section. Research interests of this branch include planning and conducting research on the molecular and cellular bases of selected congenital and acquired hematological disorders; developing quantitative methods to express disease severity or activity, amenable to sequential applications; studying gene expression and differentiation in erythroid cells in normal and pathological hematopoietic states; studying the molecular basis of lineage-specific differentiation of hematopoietic stem cells; and developing therapies for hemoglobinopathies and other genetic blood disorders based on the modification of target gene expression.​

Tisdale's Working Group

John Fitzgerald Tisdale, M.D.

Dr. Tisdale’s working group is researching multiple strategies in the laboratory and the clinic to cure sickle cell disease (SCD) by repairing or replacing the precursor bone marrow cells that give rise to sickled red blood cells. Bone marrow transplants from healthy donors are used successfully to treat certain blood cancers for which the course of the disease is so severe that the destruction of the patient’s own immune system through high-dose chemotherapy and radiation seems an effective compromise. However, the therapeutic balance in the case of SCD is less clear; children tolerate transplants more successfully, but they are also less imminently threatened by the disease. The success of conventional transplants in adults, whose need is more immediate, is less clear. 

The issue of immune tolerance is, of course, central to transplantation research. Dr. Tisdale has an active research program in trying to characterize tolerance and create conditions in which patients will more easily tolerate donor cells and tissues without the need for destroying the immune system or perpetual use of immunosuppressant drugs.  The program is also working on gene addition strategies that will harness the machinery of viruses to act as delivery vectors to provide a correct copy of the normal or a therapeutic gene to the patient's own bone marrow cells.  Finally, his group is working to develop the means to correct the genetic mutation by gene editing strategies among pluripotent stem cells.



Staff


Wulin Aerbajinai, M.D., Ph.D., Senior Research Fellow

301-496-6657


Kyung Chin, B.S., Biologist

301-402-6322​


Wynona Coles, M.P.H., Program Analyst

301-402-2104


Courtney Fitzhugh, M.D., Assitant Clinical Investigator

301-496-6496


Atsushi Fujita, M.D., Ph.D., Visiting Fellow


Matthew Hsieh, M.D., Staff Clinician

301-402-7687


Karen Kendrick, B.A., Program Technician

301-496-7796


Chutima Kumkhaek, Ph.D., Research Fellow

301-594-3741


Hongzhen Li, M.D., Ph.D., Senior Research Fellow

301-496-7161


Mary E. Link, B.S.N. and C.C.R.P., Nurse Specialist

301-402-3087


Wenli Liu, M.D., Staff Scientist

301-594-7583


Oswald Phang, B.S., Chemist

301-496-9925


John Tisdale, M.D., Senior Investigator

301-402-6497


Naoya Uchida, M.D., Ph.D., Staff Scientist

301-435-8073


R. Pat Weitzel, Ph.D., RTA

301-594-6261


Jianqiong Zhu, M.D., Senior Research Fellow

301-496-6962

​​